-
Intratumoral heterogeneity may become another important marker of lung cancer immunotherapy
Time of Update: 2021-04-16
html" target="_blank">biomarkers In the past ten years, immune checkpoint inhibitors (ICIs) have made significant progress in the clinical treatment of tumors.
In order to solve this clinical problem and enable more patients to benefit from treatment, Professor Zhang’s team optimized the algorithm of intratumoral heterogeneity and verified that bioon.
-
Fudan University Affiliated Tumor Hospital implements "one-stop" radiotherapy program landing
Time of Update: 2021-04-16
" Director Zhang Zhen said this time from 2016 After the daily treatment of patients began, the doctors, physicists and technicians of the Radiation Therapy Center of the Cancer Hospital and the United Imaging Scientific Researchers discussed, verified and clinically tested, and finally jointly contributed to this unprecedented technological innovation and clinical landing.
-
Trends in Endocrinology & Metabolism: "Starve" cancer cells, the approach and challenge of amino acid depletion therapy
Time of Update: 2021-04-16
Recently, researchers from the Princess Marsima Pediatric Cancer Center of the Netherlands published a review article titled Amino Acid Depletion Therapies: Starving Cancer Cells to Death in the sub-Journal of Cell, Trends in Endocrinology & Metabolism (IF: 11.
-
Gut: Existing imaging methods are still not effective in screening for pancreatic cancer in time!
Time of Update: 2021-04-16
This study aims to evaluate the long-term benefits of pancreatic cancer surveillance in high-risk genetically susceptible populations.
In total, 366 individuals were recruited, including 201 non-mutant relatives of familial pancreatic cancer (FPC) patients and 165 PDAC susceptible gene mutation carriers .
-
Br J Cancer: Clinical research reveals the contribution of tepotinib to patients with advanced liver cancer
Time of Update: 2021-04-16
This phase 1b/2 clinical study aims to evaluate the effect of tepotinib in patients with advanced hepatocellular carcinoma (aHCC) overexpressing MET treated with sorafenib in the United States/Europe.
-
BMC Med | Differences between men and women: the fatter the men and the thicker the waist of women, the higher the risk of colorectal cancer!
Time of Update: 2021-04-16
Recently, researchers from the University of Bristol in the United Kingdom used a naturally occurring test called Mendelian randomization to use genetic information to better understand the causality of adjustable factors and studied two different measures of obesity-namely Whether body mass index (BMI) and waist-to-hip ratio (WHR) are associated with the risk of CRC in men and women, respectively.
-
Kangfang Bio-PD-1 obtained FDA breakthrough therapy qualification, third-line treatment of metastatic nasopharyngeal carcinoma
Time of Update: 2021-04-14
FDAIn September 2020, Kangfang Bio announced that the registered clinical trial of Paimrizumab for the third-line treatment of metastatic nasopharyngeal carcinoma reached the primary endpoint of objective response rate (ORR) assessed by independent imaging, after previous multi-line treatment Among the patients with nasopharyngeal cancer, they have shown good clinical efficacy and safety, and will communicate with NMPA before applying for new drugs.
-
MPN Case Inventory | Analysis of Difficulties in Diagnosis and Treatment of MPN Disease
Time of Update: 2021-04-14
Auxiliary blood test: HGB: 57g/L Biochemistry: LDH: 2486U/L Abdominal color Doppler ultrasound: liver size and shape is normal, spleen color super thick meridian: 110mm, oblique meridian 281mm Gene detection: JAK2V617F mutation positive case diagnosis Post-PV MF (IPSS: 2 points, DIPSS: 3 points, intermediate risk-2) After diagnosis and treatment, thalidomide 50 mg qd, stanozolol 2 mg bid, blood transfusion, diuresis, and infection control after 2020-02.
-
The world's fifth CAR-T therapy was approved by the FDA for marketing, targeting BCMA
Time of Update: 2021-04-14
On March 26, 2021, Abecma (idecabtagene vicleucel; ide-cel), a CAR-T cell therapy product jointly developed by BMS (Bristol-Myers Squibb) and Bluebird (Bluebird Bio) , was officially approved for marketing by the FDA .
-
Lancet Oncol: Active symptom control combined with FOLFOX chemotherapy can effectively prolong the survival of patients with advanced biliary cancer in second-line treatment
Time of Update: 2021-04-14
Recently, The Lancet Oncology published a study in which patients with advanced biliary tract cancer who had progressed from first-line chemotherapy (cisplatin + gemcitabine) were treated with active symptom control (ACS) combined with FOLFOX regimen (leucovorin + fluorouracil + oxa) in the second-line treatment.
-
Progress in the treatment of newly diagnosed diffuse large B-cell lymphoma
Time of Update: 2021-04-14
The results of a phase II clinical trial showed that [11], newly diagnosed patients with limited-stage DLBCL can achieve CMR after only 3 cycles of R-CHOP treatment, using PET/CT assessment.
-
Severe rash occurred after cytarabine chemotherapy. Can subsequent chemotherapy continue to be used?
Time of Update: 2021-04-14
Skin adverse reactions caused by cytarabine are more common, usually manifested as mycelial outbreaks, which mainly occur in the site of the bone, the intertrigeminal zone, or to a lesser extent, the elbows, knees, neck, and ears.
-
Up-regulation of histone deacetylase 6 is associated with the malignancy of melanoma and the prognosis of patients
Time of Update: 2021-04-14
In recent years, more and more researchers have devoted themselves to exploring the biological characteristics of melanoma, but there are no clinical biomarkers that can predict the occurrence and development of melanoma.
-
A must-see for women!
Time of Update: 2021-04-14
Although many women take the recommended dose of tamoxifen (20 mg) for a long time, although it can prevent breast cancer, it also causes a variety of side effects that cannot be ignored.
-
Genxi Bio announced the completion of the first patient enrollment in the Phase I/II registered clinical study of donor-derived allogeneic CAR-T cell therapy GC007g for relapsed/refractory B-ALL
Time of Update: 2021-04-14
Recent popular reports from Yimaike ★ GC019F CAR-T developed by Genxi Bio based on the FasTCAR platform for adult patients with relapsed or refractory B-ALL was approved by the IND to enter the regis
-
Cabozantinib combined with nivolumab prolongs the overall survival of patients with advanced kidney cancer
Time of Update: 2021-04-14
This article from the NEJM meta-Journal (NEJM Journal Watch) Cabozantinib plus Nivolumab Improves Overall Survival in Advanced Kidney Cancer Cabozantinib joint Carolina Wu Li You monoclonal antibody in patients with advanced kidney cancer prolongs overall survival comment author: Robert Dreicer, MD, MS , MACP, FASCO in patients receiving combination therapy, progression-free survival and overall survival are longer than those receiving TKI sunitinib treatment.
-
Open a new era in the treatment of cholangiocarcinoma!
Time of Update: 2021-04-14
On March 29, local time, Incyte announced that the European Commission (EC) formally approved the listing application of the powerful FGFR kinase inhibitor Pemazyre (pemigatinib), which is mainly used for the treatment of already received treatment, FGFR2 fusion or rearrangement, and inoperable Resected locally advanced or metastatic cholangiocarcinoma (cholangiocarcinoma) patients.
-
CStone's retransmission of precision treatment drug Taijihua® is approved for marketing, and Chinese patients with gastrointestinal stromal tumors usher in new therapies
Time of Update: 2021-04-14
Approved for the treatment of unresectable or metastatic GIST adult patients with PDGFRA exon 18 mutation is based on an open-label, multi-center phase I/II clinical study aimed at evaluating Taijihua?
-
Review and inventory | 2021 EBMT annual meeting research progress collection
Time of Update: 2021-04-14
Autologous anti-CD19 chimeric antigen receptor (CAR) was announced at this EBMT annual meeting- Interim analysis results of ZUMA-12 study of T-cell therapy Axi-cel as the first-line treatment of patients with large B-cell lymphoma (LBCL).
-
【Nature Sub-Journal】First!
Time of Update: 2021-04-14
Source: "Nature Communications" Scientists at the Australian Children's Cancer Institute discovered that a cellular protein called ALYREF plays a vital role in accelerating the role of the cancer driver gene MYCN in neuroblastoma.
